$52.5 B

SHPG Mkt cap, 15-Oct-2018

Shire Revenue Breakdown

Embed Graph

Shire revenue breakdown by business segment: 11.6% from Internal Medicine, 30.2% from Immunology, 18.4% from Neuroscience, 10.0% from Genetic Diseases, 26.2% from Hematology and 3.6% from Other

Shire Income Statement

Annual

GBPFY, 1996FY, 1997FY, 1998FY, 1999FY, 2000FY, 2001FY, 2002FY, 2003FY, 2004FY, 2005FY, 2006FY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

5.5m4.7m14.1m18.2m26.5m19.2m20.1m29.0m32.4m119.6m108.0m98.3m114.0m111.4m103.4m109.3m120.6m122.3m67.1m58.2m47.6m52.3m

Revenue growth, %

(9%)16%(2%)(7%)6%10%1%(45%)9467%70%39%

Operating expense total

6.0m6.5m13.9m20.4m27.2m32.6m36.3m39.1m41.8m101.5m159.8m95.1m100.7m104.7m106.5m113.1m120.3m123.2m70.1m55.9m46.4m5.3b

Depreciation and amortization

1.2b1.8b

EBITDA

32.9m40.9m34.4m(1.1m)(1.5m)3.0m1.7m(433.0k)3.7m1.8m

EBITDA margin, %

33%36%31%(1%)(1%)2%1%(1%)6%4%

EBIT

(526.4k)(1.9m)175.0k(2.2m)(735.0k)(13.3m)(16.1m)(10.1m)(9.4m)18.2m(51.8m)3.3m13.3m6.7m(3.1m)(3.9m)354.0k(905.0k)(3.1m)2.3m1.1m2.5b

EBIT margin, %

(10%)(40%)1%(12%)(3%)(69%)(80%)(35%)(29%)15%(48%)3%12%6%(3%)(4%)0%(1%)(5%)4%2%4698%

Pre tax profit

(939.6k)(1.9m)1.2m(762.0k)(179.0k)(11.8m)(14.0m)(10.7m)(10.5m)22.3m(54.2m)5.1m15.8m7.1m(2.9m)(3.2m)1.3m626.0k(5.7m)5.6m2.4m6.3m

Income tax expense

(404.0k)4.2m(4.4m)(16.6m)(11.3m)2.4m(691.0k)(2.4m)990.0k503.0k303.0k947.0k2.9m(2.6m)28.0k(3.2m)

Net Income

(939.6k)(1.9m)1.2m(762.0k)(179.0k)(12.2m)(9.8m)(15.1m)(10.5m)5.7m(65.5m)7.5m15.1m4.7m(1.9m)(2.7m)1.6m1.6m(2.9m)2.9m2.5m3.1m

Shire Balance Sheet

Annual

GBPFY, 1996FY, 1997FY, 1998FY, 1999FY, 2000FY, 2001FY, 2002FY, 2003FY, 2004FY, 2005FY, 2006FY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

45.7k219.3k17.0k4.0k135.5m528.8m472.4m

Accounts Receivable

5.0k4.0k1.2b2.6b3.0b

Prepaid Expenses

197.4m806.3m795.3m

Inventories

455.3m544.8m635.4m3.6b3.3b

Current Assets

6.1m7.4m22.4m16.0m21.0m41.2m21.4m5.9m7.4m72.4m51.1m75.3m116.7m143.6m148.2m145.6m148.6m156.6m151.6m158.9m7.5b175.1m

PP&E

205.5k188.0k432.0k507.0k12.1m12.3m12.7m20.7m19.5m21.3m23.3m22.9m26.9m38.8m37.4m40.7m38.7m37.0m8.4m7.0m6.5b25.0k

Goodwill

225.0k166.0k4.1b17.9b19.8b

Total Assets

6.4m7.6m22.8m16.5m33.1m53.5m34.1m26.6m26.9m273.3m158.9m151.2m170.4m182.9m186.0m186.7m187.6m193.9m178.7m181.9m67.0b185.4m

Accounts Payable

398.1k533.1k486.0k1.0m2.0m594.0k673.0k88.0k1.3m1.9m730.0k356.0k2.9m295.0k4.6m2.5m3.3m1.8m424.0k486.0k4.3b238.0k

Short-term debt

1.5b3.1b2.8b

Current Liabilities

1.5m4.6m15.9m10.3m27.1m59.2m49.6m57.2m67.9m81.1m32.1m14.4m15.7m18.3m21.6m22.0m20.4m23.6m13.0m12.1m7.7b7.9m

Long-term debt

69.9m19.9b16.8b

Non-Current Liabilities

227.5m226.7m227.2m3.6m6.6m5.5m5.5m4.3m3.4m292.0k113.0k30.3b50.0k

Total Debt

278.0k1.2m2.9m4.8m4.9m2.9m540.0k56.0k124.0k1.6b19.9b19.5b

Total Liabilities

1.5m4.6m15.9m10.3m27.1m59.2m49.6m57.2m67.9m308.6m258.8m241.6m19.3m24.9m27.0m27.5m24.6m26.9m13.2m12.2m38.1b8.0m

Common Stock

58.9m81.3m81.6m

Additional Paid-in Capital

6.1m6.1m6.1m6.1m6.1m6.1m6.1m6.1m6.1m6.1m6.1m6.1m230.6m230.6m230.6m230.6m230.6m230.6m230.6m230.6m24.7b230.6m

Retained Earnings

(939.6k)(1.9m)1.2m(762.0k)(179.0k)(12.2m)(9.8m)(15.1m)(10.5m)5.7m(65.5m)7.5m15.1m4.7m(1.9m)(2.7m)1.6m1.6m(2.9m)2.9m5.9b3.1m

Total Equity

4.9m3.0m6.9m6.2m6.0m(5.7m)(15.5m)(30.5m)(41.1m)(35.3m)(99.9m)(90.4m)151.1m157.9m159.0m159.2m163.0m167.0m165.4m169.8m28.9b177.4m

Debt to Equity Ratio

0.1 x0.2 x0.5 x0.8 x-0.9 x-0.2 x0 x0 x0 x9.3 x0.7 x110.1 x

Debt to Assets Ratio

0 x0.1 x0.2 x0.1 x0.1 x0.1 x0 x0 x0 x8.7 x0.3 x105.4 x

Financial Leverage

1.3 x2.5 x3.3 x2.7 x5.5 x-9.4 x-2.2 x-0.9 x-0.7 x-7.7 x-1.6 x-1.7 x1.1 x1.2 x1.2 x1.2 x1.2 x1.2 x1.1 x1.1 x2.3 x1 x

Quarterly

USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018

Cash

74.3m64.0m44.9m69.0m693.4m728.6m369.0m263.7m209.3m

Accounts Receivable

1.1b1.1b1.3b1.3b2.4b2.6b2.6b2.8b2.8b

Prepaid Expenses

216.6m221.6m215.0m314.4m733.6m665.3m787.2m778.5m779.9m

Inventories

588.7m632.8m608.9m680.0m5.8b4.9b3.3b3.3b3.4b

Current Assets

2.5b2.5b2.7b2.4b9.7b8.9b7.1b7.2b7.3b7.9b

PP&E

821.9m816.7m795.9m837.6m6.6b6.5b6.5b6.6b6.6b

Goodwill

4.2b4.2b4.3b6.9b13.0b14.9b19.1b19.5b19.7b

Total Assets

17.7b17.0b17.5b24.1b70.7b69.8b66.2b67.2b67.5b

Accounts Payable

2.0b1.9b2.0b2.0b3.7b4.0b3.6b3.8b3.9b3.9b

Short-term debt

2.6b2.2b2.0b2.2b2.7b2.7b3.0b3.2b2.6b

Current Liabilities

4.9b4.3b4.3b4.3b6.9b7.1b7.0b7.4b7.5b

Long-term debt

78.7m73.9m70.7m4.7b21.3b21.0b19.5b18.4b18.0b

Non-Current Liabilities

3.8b3.6b3.6b9.4b34.1b32.9b29.4b2.8b27.4b

Total Debt

2.6b2.3b2.1b6.9b24.0b23.7b22.5b21.6b20.6b

Total Liabilities

8.7b7.9b7.9b13.8b41.0b40.0b36.4b35.9b34.8b

Common Stock

58.9m58.9m58.9m59.0m81.0m81.3m81.4m81.5m81.5m

Additional Paid-in Capital

4.4b4.4b4.4b4.5b24.5b24.6b24.9b25.0b25.0b

Retained Earnings

5.0b5.1b5.5b6.2b5.9b5.5b6.3b6.3b6.9b

Total Equity

9.0b9.1b9.6b10.3b29.8b29.8b29.7b31.3b32.7b37.4b

Debt to Equity Ratio

0.3 x0.3 x0.2 x0.7 x0.8 x0.8 x0.8 x0.7 x0.6 x

Debt to Assets Ratio

0.1 x0.1 x0.1 x0.3 x0.3 x0.3 x0.3 x0.3 x0.3 x

Financial Leverage

2 x1.9 x1.8 x2.3 x2.4 x2.3 x2.2 x2.1 x2.1 x

Shire Cash Flow

Annual

GBPFY, 1996FY, 1997FY, 1998FY, 1999FY, 2000FY, 2001FY, 2002FY, 2003FY, 2004FY, 2005FY, 2006FY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(939.6k)(1.9m)1.2m(762.0k)(179.0k)(12.2m)(9.8m)(15.1m)(10.5m)5.7m(65.5m)7.5m15.1m4.7m(1.9m)(2.7m)1.6m1.6m(2.9m)2.9m2.5m3.1m

Depreciation and Amortization

324.4m407.3m637.2m1.5b2.3b

Accounts Receivable

(211.4m)(701.7m)(487.6m)

Inventories

(63.2m)(255.8m)(145.1m)

Accounts Payable

109.2m621.6m(526.8m)

Cash From Operating Activities

2.3b2.7b4.3b

Purchases of PP&E

(157.0m)(114.7m)(648.7m)(798.8m)

Cash From Investing Activities

(360.9m)(4.0b)(5.6b)(18.1b)(700.9m)

Short-term Borrowings

(3.1b)(16.4b)(7.7b)

Dividends Paid

(134.4m)(171.3m)(281.3m)

Cash From Financing Activities

439.0m15.8b(3.6b)

Net Change in Cash

(2.8b)393.3m(56.4m)

Interest Paid

(29.9m)(14.5m)(20.0m)(284.0m)554.2m

Income Taxes Paid

947.0k2.9m(145.9m)(431.0m)524.7m

Quarterly

USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Net Income

410.4m570.0m1.0b419.0m256.9m(129.9m)375.0m615.3m1.2b

Depreciation and Amortization

120.6m291.8m457.4m168.9m429.8m877.8m486.9m1.0b1.6b

Accounts Receivable

(85.1m)(84.9m)(288.1m)(100.9m)(181.0m)(411.2m)(35.3m)(181.5m)(301.5m)

Inventories

(22.0m)(37.4m)(21.7m)(32.2m)(116.4m)(228.0m)(151.8m)(171.6m)(245.2m)

Accounts Payable

77.5m(39.8m)56.5m(154.6m)342.7m315.2m(671.5m)(445.1m)(557.8m)

Cash From Operating Activities

561.6m1.0b1.6b389.5m980.4m1.5b459.1m1.7b2.7b

Purchases of PP&E

(22.3m)(39.8m)(62.1m)(51.6m)(179.1m)(402.5m)(212.5m)(391.1m)(565.5m)

Cash From Investing Activities

(5.2b)(5.2b)(5.6b)(5.7b)(17.6b)(17.8b)(219.8m)(355.9m)(491.2m)

Short-term Borrowings

(535.2m)(1.5b)(2.5b)(995.1m)(1.5b)(14.6b)(1.8b)(3.5b)(5.7b)

Dividends Paid

(110.2m)(110.2m)(130.2m)(130.2m)(234.7m)(234.7m)

Cash From Financing Activities

1.7b1.3b1.1b5.2b17.2b16.9b(401.8m)(1.6b)(2.6b)

Net Change in Cash

(2.9b)(2.9b)(2.9b)(66.5m)557.9m593.1m(159.8m)(265.1m)(319.5m)

Interest Paid

(5.0m)(9.9m)(13.1m)(13.9m)(111.4m)223.4m108.2m267.0m434.9m

Income Taxes Paid

48.8m(65.2m)(97.5m)(89.6m)(253.7m)355.8m23.1m176.0m308.0m
Report incorrect company information

Shire Operating Metrics

FY, 2014FY, 2015FY, 2016FY, 2017

Phase I Trials Products

7 6 6 7

Phase II Trials Products

11 6 10 10

Phase III Trials Products

7 14 17 15

Phase Approved

2 3 4 7

Projects in R&D Pipeline

27 29 37 40

Countries

68 72 100 100

Preclinical Phase Products

33 33 35 35

Franchises

7

Manufacturing Sites

14

New Product Launches

50

Products Marketed

40
Report incorrect company information

Shire Human Capital

Shire's employees are reported to be approximately 52% female and 48% male.

Gender

FY, 2016FY, 2015
Male48 %50 %
Female52 %50 %
Report incorrect company information